Purpose of application
Public Summary DocumentApplication No. 1525 - Low dose-rate (LDR) brachytherapy for intermediate and high-risk prostate cancerApplicant: BXTAccelyon Australia Pty LtdDate of MSAC consideration:MSAC 76th Meeting, 1-2 August 2019Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC websitePurpose of application An application requesting Medicare Benefits Schedule (MBS) listing of LDR Brachytherapy (LDR-BT) for intermediate and high-risk prostate cancer was received from MedTechnique on behalf of BXTAccelyon Australia Pty Ltd by the Department of Health.MSAC’s advice to the MinisterAfter considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support public funding for LDR-BT boost (following primary external beam radiotherapy [EBRT]) for intermediate and high-risk prostate cancer. MSAC considered that the limited comparative safety and effectiveness evidence was too uncertain relative to dose escalated (DE-EBRT), and no evidence was presented relative to treatment with high dose-rate brachytherapy (HDR-BT) boost following EBRT or radical prostatectomy (RP).Consumer summaryBXTAccelyon Australia applied for public funding for low dose-rate brachytherapy (LDR-BT) in the treatment of prostate cancer. In LDR-BT, small radioactive “seeds” are placed into the prostate gland and stay there permanently to deliver radiation close to the tumour. This is done to boost the radiation dose after a patient has already had radiation directed at the tumour from outside the body (called external beam radiotherapy, or EBRT). Other options for patients who have already had EBRT are more doses of EBRT (called dose-escalated EBRT) or temporary radiation given through a small tube into the prostate (called high dose-rate brachytherapy, or HDR-BT).LDR-BT is already listed on the MBS for use in patients who have low-risk prostate cancer. This application is requesting MBS listing for LDR-BT to be used as a radiation boost after EBRT in patients with intermediate- to high-risk prostate cancer.MSAC’s recommendation to the Commonwealth Health MinisterMSAC did not support public funding of LDR-BT for this use because there is not enough evidence to be certain of its safety and effectiveness compared with other treatment options.Summary of consideration and rationale for MSAC’s advice Application 1525 proposes that LDR-BT would be used as a radiation boost after primary EBRT, as an alternative to RP, DE-EBRT or HDR-BT boost following EBRT. MSAC noted that LDR-BT for use in low-intermediate/low–risk prostate cancer has been listed on the MBS since 2001 (MBS items 37220 and 15338). MSAC also noted that international clinical guidelines recommend LDR-BT in combination with EBRT as a treatment option for intermediate- and high-risk prostate cancer.MSAC noted two new MBS items were proposed for the urological component of the procedure and the radiation oncology component. MSAC confirmed that the item descriptor should specify that LDR-BT is intended for use as a boost following EBRT and in association with androgen blockade.MSAC confirmed that the comparators – RP, DE-EBRT and HDR-BT boost following EBRT – were appropriate. MSAC noted that these comparators are currently funded under the MBS and match those in the ratified PICO. MSAC noted consultation feedback suggesting that comparators should also include intensity modulated radiation therapy.MSAC noted that very limited evidence was presented on the comparative safety and clinical effectiveness of LDR-BT. In the ASCENDE-RT trial, adverse effects (acute genitourinary (GU) toxicity, and late gastrointestinal (GI) and GU morbidity) were more frequent in the EBRT+LDR-BT boost arm than the DE-EBRT arm, and health-related quality of life scores were lower. No statistically significant differences were reported for serious adverse events (AEs) or the frequency of erectile dysfunction. Given that this application is for radiation therapy and the importance of certainty regarding radiation safety, MSAC concluded that EBRT plus LDR-BT has inferior safety relative to DE-EBRT.However, no safety data were provided comparing EBRT+LDR-BT boost with RP or EBRT+HDR-BT boost. MSAC therefore concluded that EBRT+LDR-BT boost has uncertain safety relative to RP and EBRT+HDR-BT boost.MSAC noted that it is possible that the AEs observed in the trial may be avoidable with improvements in planning and modern imaging techniques that have occurred since the trial was conducted. However, without evidence, this remains uncertain.MSAC noted that evidence for clinical effectiveness was from the ASCENDE-RT trial and a retrospective cohort study. The ASCENDE-RT trial suggested superior effectiveness of EBRT+LDR-BT boost versus DE-EBRT for biochemical progression-free survival. However, there was no difference in overall survival, metastasis-free survival or prostate cancer–specific survival, and the study was not powered or long enough to assess survival outcomes. The retrospective cohort study suggested better overall survival for EBRT+LDR-BT boost than for DE-EBRT. However, this study was at a high risk of bias and, potentially, low applicability. MSAC therefore concluded that EBRT+LDR-BT boost has superior effectiveness for biochemical progression-free survival, but uncertain effectiveness for overall survival, metastasis-free survival or prostate cancer–specific survival, relative to DE-EBRT.No data were provided comparing effectiveness of EBRT+LDR-BT boost with either RP or EBRT+HDR-BT boost. MSAC therefore concluded that EBRT+LDR-BT boost has uncertain effectiveness relative to EBRT+HDR-BT boost and RP.MSAC noted that the economic model was modified to address concerns raised by ESC. MSAC accepted that the revised model is likely to be appropriate and now shows that use of LDR-BT as a boost following EBRT appears to be cost-effective based on the revised inputs used. MSAC noted that cost-effectiveness is sustained or increased over a 20–30-year time horizon based on life year and quality-adjusted life year (QALY) outcomes.MSAC noted that the amended financial model estimates a cost to the MBS of approximately $400,000 in Year?5.MSAC advised that any future resubmission should include:comparative safety data based on up-to date practice, ideally for all three comparators;effectiveness data for the other two comparators (RP and EBRT+HDR-BT boost); andcost-effectiveness analyses should be updated to reflect any newly relevant comparative safety and effectiveness data.MSAC suggested that the Medical Research Future Fund may be a suitable vehicle for providing more evidence.MSAC considered that States, Territories and others paying for the seeds should be made aware of the lack of evidence for comparative safety and effectiveness of LDR-BT boost (following EBRT) for patients with intermediate and high-risk prostate cancer. BackgroundThis is the first submission for LDR Brachytherapy for intermediate and high-risk prostate cancer. MSAC has not previously considered this application.Prerequisites to implementation of any funding adviceThe intervention does not require a new device, a number of brachytherapy-related items are already listed on the ARTG (Australian Register of Therapeutic Goods). Proposal for public fundingThe applicant proposed two new MBS items to cover the urological component and radiation oncology component of LDR-BT for use as a boost to EBRT in patients with high-intermediate and high-risk prostate cancer. The proposed MBS item descriptors are summarised in Table 1.Table SEQ Table \* ARABIC 1Applicant proposed MBS item descriptorCategory 3 – Therapeutic proceduresPROSTATE, radioactive seed implantation (radiation oncology component), using transrectal ultrasound guidance, for localised (non-metastatic) prostatic malignancy classified as high-intermediate risk (defined as having a prostate specific antigen (PSA) of 10-20 ng/ml and a Gleason score of 7 and a tumour classified as T2b-c) or high risk (defined as having a PSA of greater than 20 ng/ml and/or a Gleason score of 8-10 and/or a tumour classified as T3). It is recommended the procedure only be performed as ‘boost’ treatment, in addition to external beam radiotherapy, at an approved site in association with a urologist.Fee: $935.60PROSTATE, radioactive seed implantation (urological component), using transrectal ultrasound guidance, for localised (non-metastatic) prostatic malignancy classified as high-intermediate risk (defined as having a prostate specific antigen (PSA) of 10-20 ng/ml and a Gleason score of 7 and a tumour classified as T2b-c) or high risk (defined as having a PSA of greater than 20 ng/ml and/or a Gleason score of 8-10 and/or a tumour classified as T3). It is recommended the procedure only be performed as ‘boost’ treatment, in addition to external beam radiotherapy, at an approved site in association with a radiation oncologist.Fee: $1,044.20Source: Table 1, pp20-21 of the CAThe Department proposed the following item descriptors in Table 2. Table 2Department proposed MBS item descriptorCategory 3 – Therapeutic ProceduresPROSTATE, radioactive seed implantation (radiation oncology component), using transrectal ultrasound guidance, for localised (non-metastatic) prostatic malignancy classified as high-intermediate risk (defined as having a prostate specific antigen (PSA) of 10-20 ng/ml and a Gleason score of 7 and a tumour classified as T2b-c) or high risk (defined as having a PSA of greater than 20 ng/ml and/or a Gleason score of 8-10 and/or a tumour classified as T3). For the population above this procedure will be rebated if it is performed at an approved site as a boost treatment in addition to external beam radiotherapy and in association with androgen blockade, in association with an urologist.MBS Fee: $935.60MBS Benefit (Rebate): 75% = $701.70 (in-hospital / admitted patient) AND 85% = $853.90 (out-of-hospital / outpatient) = higher than 85% because of the provision of higher rebates for outpatient services when MBS fee is higherCategory 3 – Therapeutic ProceduresPROSTATE, radioactive seed implantation (urological component), using transrectal ultrasound guidance, for localised (non-metastatic) prostatic malignancy classified as high-intermediate risk (defined as having a prostate specific antigen (PSA) of 10-20 ng/ml and a Gleason score of 7 and a tumour classified as T2b-c) or high risk (defined as having a PSA of greater than 20 ng/ml and/or a Gleason score of 8-10 and/or a tumour classified as T3). For the population above this procedure will be rebated if it is performed at an approved site as a boost treatment in addition to external beam radiotherapy and in association with androgen blockade, in association with a radiation oncologist MBS Fee: $1,044.20MBS Benefit (Rebate): 75% = $783.15 (in-hospital / admitted patient only) Summary of Public Consultation Feedback/Consumer IssuesTargeted consultation feedback was received from three organisations which supported the listing of LDR-BT boost on the MBS, citing superior biochemical progression-free survival (b-PFS) and freedom from failure of LDR-BT boost compared to DE-EBRT treatment in the ASCENDE-RT trial (Morris, Tyldesley et al. 2017).Proposed intervention’s place in clinical managementThe current and proposed algorithms are depicted in Figure 1 and Figure 2. The difference between the current clinical management algorithm and the proposed clinical management algorithm for high-intermediate and high-risk prostate cancer is that there would be an option for patients to receive LDR-BT boost following primary EBRT treatment.LDR-BT can be provided in both the public and private hospital sector, performed at an approved site where radiation oncology services may be performed lawfully under the law of the State or Territory in which the site is located. The applicant advised, at present, LDR-BT is only available in a limited number (25) of centres in Australia. The proposed clinical algorithm is identical to that in the ratified PICO.Figure 1Current and proposed (shaded) clinical treatment algorithm for patients with intermediate and high-risk prostate cancer – part 1 (continued in Figure 2)Abbreviations: ADT=androgen deprivation therapy; DRE=digital rectal examination; EBRT=external beam radiation therapy; DE-EBRT=dose-escalated external beam radiation therapy; HDR-BT=high-dose rate brachytherapy; LDR-BT=low-dose rate brachytherapy; MRI=magnetic resonance imaging; PSA=Prostate Specific AntigenFigure 2Current and proposed clinical treatment algorithm for patients with intermediate and high-risk prostate cancer – part 2 (continued from Figure 1)Abbreviations: ADT=androgen deprivation therapy; CT=computed tomography; DRE=digital rectal examination; MRI=magnetic resonance imaging; PLND=pelvic lymph node dissection; PSA=Prostate Specific Antigen; RP=radical prostatectomyComparator Three comparators have been identified for LDR-BT boost for high-intermediate and high-risk prostate cancer treatment: Radical prostatectomy (RP) (i.e. a surgical treatment);Dose escalated (DE)–EBRT; andHigh-dose-rate brachytherapy (HDR-BT) boost, following EBRT; referred to as EBRT+HDR-BT in application).The intervention and the two radiotherapy comparators all involve initial EBRT treatment, but the difference lies in the type of additional radiation delivered as a ‘boost’. Subsequent ‘boost’ may be delivered as additional doses of the same procedure (DE-EBRT), through permanent implantation of LDR-BT seeds, or through temporary HDR-BT ADDIN EN.CITE <EndNote><Cite><Author>Duchesne</Author><Year>2011</Year><RecNum>10</RecNum><DisplayText>(Duchesne 2011)</DisplayText><record><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="9avz5tt06x90d4e0tzkvwse8p2xwawpdxzva" timestamp="1544589141">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Duchesne, G.</author></authors></contributors><auth-address>Peter MacCallum Cancer Centre, University of Melbourne and Monash University, Melbourne, Victoria. gillian.duchesne@</auth-address><titles><title>Localised prostate cancer - current treatment options</title><secondary-title>Aust Fam Physician</secondary-title><alt-title>Australian family physician</alt-title></titles><periodical><full-title>Aust Fam Physician</full-title><abbr-1>Australian family physician</abbr-1></periodical><alt-periodical><full-title>Aust Fam Physician</full-title><abbr-1>Australian family physician</abbr-1></alt-periodical><pages>768-71</pages><volume>40</volume><number>10</number><edition>2011/10/18</edition><keywords><keyword>Humans</keyword><keyword>Male</keyword><keyword>Neoplasm Grading</keyword><keyword>Neoplasm Staging</keyword><keyword>Prostatectomy</keyword><keyword>Prostatic Neoplasms/*pathology/radiotherapy/surgery/*therapy</keyword><keyword>Watchful Waiting</keyword></keywords><dates><year>2011</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>0300-8495 (Print)
0300-8495</isbn><accession-num>22003477</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>(Duchesne 2011). The comparators are currently funded by the MBS, and match those in the ratified PICO.In Australia, the CA stated that the most commonly used treatment modalities for localised prostate cancer include surgery, radiotherapy (external beam or interstitial brachytherapy) and hormonal therapy PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NaWxsZXI8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxS
ZWNOdW0+NDwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oTWlsbGVyIDIwMTIsIFZJQy1QQ1IgMjAxNSk8
L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+NDwvcmVjLW51bWJlcj48Zm9yZWlnbi1r
ZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Ijlhdno1dHQwNng5MGQ0ZTB0emt2d3NlOHAyeHdhd3Bk
eHp2YSIgdGltZXN0YW1wPSIxNTQ0NTg4MTk4Ij40PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10
eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1
dGhvcnM+PGF1dGhvcj5NaWxsZXIsIEouPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz
PjxhdXRoLWFkZHJlc3M+KE1pbGxlcikgQWxmcmVkIEhlYWx0aCwgUmFkaWF0aW9uIE9uY29sb2d5
LCBNZWxib3VybmUsIEF1c3RyYWxpYSYjeEQ7Si4gTWlsbGVyLCBBbGZyZWQgSGVhbHRoLCBSYWRp
YXRpb24gT25jb2xvZ3ksIE1lbGJvdXJuZSwgQXVzdHJhbGlhPC9hdXRoLWFkZHJlc3M+PHRpdGxl
cz48dGl0bGU+QXVzdHJhbGlhbiBwcm9zdGF0ZSBicmFjaHl0aGVyYXB5PC90aXRsZT48c2Vjb25k
YXJ5LXRpdGxlPlJhZGlvdGhlcmFweSBhbmQgT25jb2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3Rp
dGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5SYWRpb3RoZXJhcHkgYW5kIE9uY29sb2d5PC9m
dWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+UzI0PC9wYWdlcz48dm9sdW1lPjIpPC92b2x1
bWU+PGtleXdvcmRzPjxrZXl3b3JkPmJyYWNoeXRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+cHJv
c3RhdGU8L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tleXdvcmQ+PGtleXdvcmQ+QXVzdHJhbGlh
PC9rZXl3b3JkPjxrZXl3b3JkPm1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+cGxhbnQgc2VlZDwva2V5
d29yZD48a2V5d29yZD5yaXNrPC9rZXl3b3JkPjxrZXl3b3JkPmdvdmVybm1lbnQ8L2tleXdvcmQ+
PGtleXdvcmQ+cHJvc3RhdGUgY2FuY2VyPC9rZXl3b3JkPjxrZXl3b3JkPnByb3N0YXRlY3RvbXk8
L2tleXdvcmQ+PGtleXdvcmQ+cGF0aWVudDwva2V5d29yZD48a2V5d29yZD5wdWJsaWMgaG9zcGl0
YWw8L2tleXdvcmQ+PGtleXdvcmQ+cHJvY2VkdXJlczwva2V5d29yZD48a2V5d29yZD5pbXBsYW50
PC9rZXl3b3JkPjxrZXl3b3JkPnByaXZhdGUgaG9zcGl0YWw8L2tleXdvcmQ+PGtleXdvcmQ+cG9w
dWxhdGlvbjwva2V5d29yZD48a2V5d29yZD5yb2JvdGljczwva2V5d29yZD48a2V5d29yZD5ob3Nw
aXRhbCBwYXRpZW50PC9rZXl3b3JkPjxrZXl3b3JkPmluc3VyYW5jZTwva2V5d29yZD48a2V5d29y
ZD5ob3NwaXRhbCBwbGFubmluZzwva2V5d29yZD48a2V5d29yZD5oZWFsdGggY2FyZSBzeXN0ZW08
L2tleXdvcmQ+PGtleXdvcmQ+ZnVuZGluZzwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVz
PC9rZXl3b3JkPjxrZXl3b3JkPmhlYWx0aCBjYXJlIHBlcnNvbm5lbDwva2V5d29yZD48a2V5d29y
ZD5tZWRpY2FyZTwva2V5d29yZD48a2V5d29yZD5jcnlvdGhlcmFweTwva2V5d29yZD48a2V5d29y
ZD5tYXJrZXQ8L2tleXdvcmQ+PGtleXdvcmQ+cHJpdmF0ZSBoZWFsdGggaW5zdXJhbmNlPC9rZXl3
b3JkPjxrZXl3b3JkPmxvdyBkcnVnIGRvc2U8L2tleXdvcmQ+PGtleXdvcmQ+ZXh0ZXJuYWwgYmVh
bSByYWRpb3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Y2hlbW90aGVyYXB5PC9rZXl3b3JkPjxr
ZXl3b3JkPmRpYWdub3Npczwva2V5d29yZD48a2V5d29yZD5jaXR5PC9rZXl3b3JkPjxrZXl3b3Jk
PmRlYXRoPC9rZXl3b3JkPjxrZXl3b3JkPnNhZmV0eTwva2V5d29yZD48a2V5d29yZD5tZWRpY2Fs
IHNwZWNpYWxpc3Q8L2tleXdvcmQ+PGtleXdvcmQ+ZWNvbm9taWNzPC9rZXl3b3JkPjxrZXl3b3Jk
PmhlYWx0aCBjYXJlIHF1YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+b3JnYW5pemF0aW9uIGFuZCBt
YW5hZ2VtZW50PC9rZXl3b3JkPjxrZXl3b3JkPmZvbGxvdyB1cDwva2V5d29yZD48a2V5d29yZD50
cmFuc3JlY3RhbCB1bHRyYXNvbm9ncmFwaHk8L2tleXdvcmQ+PGtleXdvcmQ+aGlnaCBpbnRlbnNp
dHkgZm9jdXNlZCB1bHRyYXNvdW5kPC9rZXl3b3JkPjxrZXl3b3JkPmlvZGluZSAxMjU8L2tleXdv
cmQ+PGtleXdvcmQ+cHJvdG9uPC9rZXl3b3JkPjxrZXl3b3JkPmFuZHJvZ2VuPC9rZXl3b3JkPjxr
ZXl3b3JkPnBhbGxhZGl1bTwva2V5d29yZD48a2V5d29yZD5jZXNpdW08L2tleXdvcmQ+PGtleXdv
cmQ+Z3Vhbm9zaW5lIGRpcGhvc3BoYXRlPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFy
PjIwMTI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5NYXk8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl
cz48aXNibj4wMTY3LTgxNDA8L2lzYm4+PGFjY2Vzc2lvbi1udW0+NzA4MzcwNTQ8L2FjY2Vzc2lv
bi1udW0+PHdvcmstdHlwZT5Db25mZXJlbmNlIEFic3RyYWN0PC93b3JrLXR5cGU+PHVybHM+PHJl
bGF0ZWQtdXJscz48dXJsPmh0dHA6Ly9lenByb3h5LmxpYnJhcnkudXN5ZC5lZHUuYXUvbG9naW4/
dXJsPWh0dHA6Ly9vdmlkc3Aub3ZpZC5jb20vb3ZpZHdlYi5jZ2k/VD1KUyZhbXA7Q1NDPVkmYW1w
O05FV1M9TiZhbXA7UEFHRT1mdWxsdGV4dCZhbXA7RD1lbWVkMTMmYW1wO0FOPTcwODM3MDU0PC91
cmw+PHVybD5odHRwOi8vREQ4R0g1WVg3Sy5zZWFyY2guc2VyaWFsc3NvbHV0aW9ucy5jb20vP3Np
ZD1PVklEOmVtYmFzZSZhbXA7aWQ9cG1pZDomYW1wO2lkPWRvaToxMC4xMDE2UzAxNjctODE0MCUy
NTI4MTIlMjUyOTcyMDI4LTUmYW1wO2lzc249MDE2Ny04MTQwJmFtcDtpc2JuPSZhbXA7dm9sdW1l
PTEwMyZhbXA7aXNzdWU9U1VQUEwuKzImYW1wO3NwYWdlPVMyNCZhbXA7cGFnZXM9UzI0JmFtcDtk
YXRlPTIwMTImYW1wO3RpdGxlPVJhZGlvdGhlcmFweSthbmQrT25jb2xvZ3kmYW1wO2F0aXRsZT1B
dXN0cmFsaWFuK3Byb3N0YXRlK2JyYWNoeXRoZXJhcHkmYW1wO2F1bGFzdD1NaWxsZXI8L3VybD48
L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPmh0dHA6Ly9keC5k
b2kub3JnLzEwLjEwMTYvUzAxNjctODE0MCUyODEyJTI5NzIwMjgtNTwvZWxlY3Ryb25pYy1yZXNv
dXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1uYW1lPkVtYmFzZTwvcmVtb3RlLWRhdGFiYXNlLW5h
bWU+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5PdmlkIFRlY2hub2xvZ2llczwvcmVtb3RlLWRh
dGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5FbmdsaXNoPC9sYW5ndWFnZT48L3JlY29yZD48L0Np
dGU+PENpdGU+PEF1dGhvcj5WSUMtUENSPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48UmVjTnVt
PjI3PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4yNzwvcmVjLW51bWJlcj48Zm9yZWlnbi1r
ZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Ijlhdno1dHQwNng5MGQ0ZTB0emt2d3NlOHAyeHdhd3Bk
eHp2YSIgdGltZXN0YW1wPSIxNTQ4MjEyMDQxIj4yNzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYt
dHlwZSBuYW1lPSJSZXBvcnQiPjI3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh
dXRob3I+VklDLVBDUjwvYXV0aG9yPjwvYXV0aG9ycz48c2Vjb25kYXJ5LWF1dGhvcnM+PGF1dGhv
cj5TYW1wdXJubyBGLCBFdmFucyBTTTwvYXV0aG9yPjwvc2Vjb25kYXJ5LWF1dGhvcnM+PHRlcnRp
YXJ5LWF1dGhvcnM+PGF1dGhvcj5Nb25hc2ggVW5pdmVyc2l0eTwvYXV0aG9yPjwvdGVydGlhcnkt
YXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5WaWN0b3JpYW4gUHJvc3RhdGUg
Q2FuY2VyIENsaW5pY2FsIFJlZ2lzdHJ5IChWSUMgUENSKSAtIEZpdmUgeWVhciByZXBvcnQ8L3Rp
dGxlPjwvdGl0bGVzPjxkYXRlcz48eWVhcj4yMDE1PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+MjAx
NTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxwdWItbG9jYXRpb24+TWVsYm91cm5lPC9wdWIt
bG9jYXRpb24+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly9wY3IucmVnaXN0cnkub3Jn
LmF1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NaWxsZXI8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxS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 EN.CITE.DATA (Miller 2012, VIC-PCR 2015). Currently, primary treatment options for patients with intermediate and high-risk prostate cancer include EBRT +/- boost or RP with concurrent or salvage parative safetyVs. RPNo data were identified comparing the safety of EBRT+LDR-BT boost to RP in people with high-intermediate and high-risk prostate cancer.Vs. DE-EBRTOne randomised controlled trial (RCT) (ASDENDE-RT; Rodda, Tyldesley et al. 2017 ) was included in the assessment of safety of EBRT+LDR-BT boost compared with DE-EBRT in patients with intermediate- and high-risk prostate cancer was found. (n=383 for assessing adverse events). The application stated that EBRT+LDR-BT boost arm had a higher number of adverse effects (acute GU toxicity, late GI and GU morbidity) compared to DE-EBRT arm. No statistically significant differences were reported for erectile dysfunction, acute grade 3 GU toxicity or acute grade 0-2 GI toxicity.Vs. EBRT+HDT-BT boostNo data were identified comparing the safety of EBRT+LDR-BT boost to EBRT+HDR-BT boost in people with high-intermediate and high-risk prostate parative effectivenessVs. RPNo data were identified comparing the effectiveness of EBRT+LDR-BT boost to RP in people with high-intermediate and high-risk prostate cancer.Vs. DE-EBRTOne RCT (3 publications PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb3JyaXM8L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxS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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb3JyaXM8L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxS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=
ADDIN EN.CITE.DATA (Morris, Tyldesley et al. 2017, Rodda, Morris et al. 2017, Rodda, Tyldesley et al. 2017) and one retrospective cohort study PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2huc29uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2huc29uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48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ADDIN EN.CITE.DATA (Johnson, Lester-Coll et al. 2017) were included in the evidence base for effectiveness of EBRT plus LDR-BT boost.The single RCT PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb3JyaXM8L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxS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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Nb3JyaXM8L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxS
ZWNOdW0+MTM8L1JlY051bT48RGlzcGxheVRleHQ+KE1vcnJpcywgVHlsZGVzbGV5IGV0IGFsLiAy
MDE3LCBSb2RkYSwgTW9ycmlzIGV0IGFsLiAyMDE3LCBSb2RkYSwgVHlsZGVzbGV5IGV0IGFsLiAy
MDE3KTwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xMzwvcmVjLW51bWJlcj48Zm9y
ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Ijlhdno1dHQwNng5MGQ0ZTB0emt2d3NlOHAy
eHdhd3BkeHp2YSIgdGltZXN0YW1wPSIxNTQ0NTg5MjUzIj4xMzwva2V5PjwvZm9yZWlnbi1rZXlz
PjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0
b3JzPjxhdXRob3JzPjxhdXRob3I+TW9ycmlzLCBXLiBKLjwvYXV0aG9yPjxhdXRob3I+VHlsZGVz
bGV5LCBTLjwvYXV0aG9yPjxhdXRob3I+Um9kZGEsIFMuPC9hdXRob3I+PGF1dGhvcj5IYWxwZXJp
biwgUi48L2F1dGhvcj48YXV0aG9yPlBhaSwgSC48L2F1dGhvcj48YXV0aG9yPk1jS2VuemllLCBN
LjwvYXV0aG9yPjxhdXRob3I+RHVuY2FuLCBHLjwvYXV0aG9yPjxhdXRob3I+TW9ydG9uLCBHLjwv
YXV0aG9yPjxhdXRob3I+SGFtbSwgSi48L2F1dGhvcj48YXV0aG9yPk11cnJheSwgTi48L2F1dGhv
cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFN1
cmdlcnksIFVuaXZlcnNpdHkgb2YgQnJpdGlzaCBDb2x1bWJpYSwgVmFuY291dmVyLCBCcml0aXNo
IENvbHVtYmlhLCBDYW5hZGE7IEJDIENhbmNlciBBZ2VuY3ktVmFuY291dmVyIENlbnRyZSwgVmFu
Y291dmVyLCBCcml0aXNoIENvbHVtYmlhLCBDYW5hZGEuIEVsZWN0cm9uaWMgYWRkcmVzczogam1v
cnJpc0BiY2NhbmNlci5iYy5jYS4mI3hEO0RlcGFydG1lbnQgb2YgU3VyZ2VyeSwgVW5pdmVyc2l0
eSBvZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFk
YTsgQkMgQ2FuY2VyIEFnZW5jeS1WYW5jb3V2ZXIgQ2VudHJlLCBWYW5jb3V2ZXIsIEJyaXRpc2gg
Q29sdW1iaWEsIENhbmFkYS4mI3hEO0RlcGFydG1lbnQgb2YgU3VyZ2VyeSwgVW5pdmVyc2l0eSBv
ZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYS4m
I3hEO0RlcGFydG1lbnQgb2YgU3VyZ2VyeSwgVW5pdmVyc2l0eSBvZiBCcml0aXNoIENvbHVtYmlh
LCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYTsgQkMgQ2FuY2VyIEFnZW5jeS1D
ZW50cmUgZm9yIHRoZSBTb3V0aGVybiBJbnRlcmlvciwgVmFuY291dmVyLCBCcml0aXNoIENvbHVt
YmlhLCBDYW5hZGEuJiN4RDtEZXBhcnRtZW50IG9mIFN1cmdlcnksIFVuaXZlcnNpdHkgb2YgQnJp
dGlzaCBDb2x1bWJpYSwgVmFuY291dmVyLCBCcml0aXNoIENvbHVtYmlhLCBDYW5hZGE7IEJDIENh
bmNlciBBZ2VuY3ktVmFuY291dmVyIElzbGFuZCBDZW50cmUsIFZhbmNvdXZlciwgQnJpdGlzaCBD
b2x1bWJpYSwgQ2FuYWRhLiYjeEQ7RGVwYXJ0bWVudCBvZiBSYWRpYXRpb24gT25jb2xvZ3ksIFVu
aXZlcnNpdHkgb2YgVG9yb250bywgU3Vubnlicm9vayBIZWFsdGggU2NpZW5jZXMgQ2VudHJlLCBU
b3JvbnRvLCBPbnRhcmlvLCBDYW5hZGEuJiN4RDtEZXBhcnRtZW50IG9mIFBvcHVsYXRpb24gT25j
b2xvZ3ksIEJDIENhbmNlciBBZ2VuY3ksIFZhbmNvdXZlciwgQnJpdGlzaCBDb2x1bWJpYSwgQ2Fu
YWRhLiYjeEQ7QkMgQ2FuY2VyIEFnZW5jeS1WYW5jb3V2ZXIgQ2VudHJlLCBWYW5jb3V2ZXIsIEJy
aXRpc2ggQ29sdW1iaWEsIENhbmFkYTsgRGVwYXJ0bWVudCBvZiBNZWRpY2luZSwgVW5pdmVyc2l0
eSBvZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFk
YS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5BbmRyb2dlbiBTdXBwcmVzc2lvbiBDb21i
aW5lZCB3aXRoIEVsZWN0aXZlIE5vZGFsIGFuZCBEb3NlIEVzY2FsYXRlZCBSYWRpYXRpb24gVGhl
cmFweSAodGhlIEFTQ0VOREUtUlQgVHJpYWwpOiBBbiBBbmFseXNpcyBvZiBTdXJ2aXZhbCBFbmRw
b2ludHMgZm9yIGEgUmFuZG9taXplZCBUcmlhbCBDb21wYXJpbmcgYSBMb3ctRG9zZS1SYXRlIEJy
YWNoeXRoZXJhcHkgQm9vc3QgdG8gYSBEb3NlLUVzY2FsYXRlZCBFeHRlcm5hbCBCZWFtIEJvb3N0
IGZvciBIaWdoLSBhbmQgSW50ZXJtZWRpYXRlLXJpc2sgUHJvc3RhdGUgQ2FuY2VyPC90aXRsZT48
c2Vjb25kYXJ5LXRpdGxlPkludCBKIFJhZGlhdCBPbmNvbCBCaW9sIFBoeXM8L3NlY29uZGFyeS10
aXRsZT48YWx0LXRpdGxlPkludGVybmF0aW9uYWwgam91cm5hbCBvZiByYWRpYXRpb24gb25jb2xv
Z3ksIGJpb2xvZ3ksIHBoeXNpY3M8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVs
bC10aXRsZT5JbnQgSiBSYWRpYXQgT25jb2wgQmlvbCBQaHlzPC9mdWxsLXRpdGxlPjxhYmJyLTE+
SW50ZXJuYXRpb25hbCBqb3VybmFsIG9mIHJhZGlhdGlvbiBvbmNvbG9neSwgYmlvbG9neSwgcGh5
c2ljczwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SW50
IEogUmFkaWF0IE9uY29sIEJpb2wgUGh5czwvZnVsbC10aXRsZT48YWJici0xPkludGVybmF0aW9u
YWwgam91cm5hbCBvZiByYWRpYXRpb24gb25jb2xvZ3ksIGJpb2xvZ3ksIHBoeXNpY3M8L2FiYnIt
MT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yNzUtMjg1PC9wYWdlcz48dm9sdW1lPjk4PC92b2x1
bWU+PG51bWJlcj4yPC9udW1iZXI+PGVkaXRpb24+MjAxNy8wMy8wNzwvZWRpdGlvbj48a2V5d29y
ZHM+PGtleXdvcmQ+QWdlIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48
a2V5d29yZD5BZ2VkLCA4MCBhbmQgb3Zlcjwva2V5d29yZD48a2V5d29yZD5BbmRyb2dlbiBBbnRh
Z29uaXN0cy8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkJyYWNoeXRoZXJhcHkv
Km1ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+Q29tYmluZWQgTW9kYWxpdHkgVGhlcmFweS9tZXRo
b2RzPC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UtRnJlZSBTdXJ2aXZhbDwva2V5d29yZD48a2V5
d29yZD5Gb2xsb3ctVXAgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5Hb25hZG90cm9waW4tUmVs
ZWFzaW5nIEhvcm1vbmUvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwv
a2V5d29yZD48a2V5d29yZD5JbnRlbnRpb24gdG8gVHJlYXQgQW5hbHlzaXM8L2tleXdvcmQ+PGtl
eXdvcmQ+SW9kaW5lIFJhZGlvaXNvdG9wZXMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3
b3JkPkthcGxhbi1NZWllciBFc3RpbWF0ZTwva2V5d29yZD48a2V5d29yZD5MeW1waGF0aWMgSXJy
YWRpYXRpb24vKm1ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29y
ZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5QZWx2aXM8L2tleXdvcmQ+PGtleXdvcmQ+
UHJvc3RhdGUtU3BlY2lmaWMgQW50aWdlbi9ibG9vZDwva2V5d29yZD48a2V5d29yZD5Qcm9zdGF0
aWMgTmVvcGxhc21zL2Jsb29kLypkcnVnIHRoZXJhcHkvKm1vcnRhbGl0eS8qcmFkaW90aGVyYXB5
PC9rZXl3b3JkPjxrZXl3b3JkPlJhZGlvdGhlcmFweSBEb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+
UmUtSXJyYWRpYXRpb24vbWV0aG9kcy9zdGF0aXN0aWNzICZhbXA7IG51bWVyaWNhbCBkYXRhPC9r
ZXl3b3JkPjxrZXl3b3JkPlRpbWUgRmFjdG9yczwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48
eWVhcj4yMDE3PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVuIDE8L2RhdGU+PC9wdWItZGF0ZXM+
PC9kYXRlcz48aXNibj4wMzYwLTMwMTY8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjgyNjI0NzM8L2Fj
Y2Vzc2lvbi1udW0+PHVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDE2
L2ouaWpyb2JwLjIwMTYuMTEuMDI2PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRh
dGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5l
bmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlJvZGRhPC9BdXRob3I+
PFllYXI+MjAxNzwvWWVhcj48UmVjTnVtPjExPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4x
MTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Ijlhdno1dHQw
Nng5MGQ0ZTB0emt2d3NlOHAyeHdhd3BkeHp2YSIgdGltZXN0YW1wPSIxNTQ0NTg5MjM0Ij4xMTwv
a2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9y
ZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+Um9kZGEsIFMuPC9hdXRob3I+
PGF1dGhvcj5Nb3JyaXMsIFcuIEouPC9hdXRob3I+PGF1dGhvcj5IYW1tLCBKLjwvYXV0aG9yPjxh
dXRob3I+RHVuY2FuLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1h
ZGRyZXNzPkJDIENhbmNlciBBZ2VuY3ksIFZhbmNvdXZlciBDZW50cmUsIFZhbmNvdXZlciwgQnJp
dGlzaCBDb2x1bWJpYSwgQ2FuYWRhLiYjeEQ7QkMgQ2FuY2VyIEFnZW5jeSwgVmFuY291dmVyIENl
bnRyZSwgVmFuY291dmVyLCBCcml0aXNoIENvbHVtYmlhLCBDYW5hZGE7IERlcGFydG1lbnQgb2Yg
U3VyZ2VyeSwgVW5pdmVyc2l0eSBvZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRp
c2ggQ29sdW1iaWEsIENhbmFkYS4mI3hEO0RlcGFydG1lbnQgb2YgUG9wdWxhdGlvbiBPbmNvbG9n
eSwgQkMgQ2FuY2VyIEFnZW5jeSwgVmFuY291dmVyIENlbnRyZSwgVmFuY291dmVyLCBCcml0aXNo
IENvbHVtYmlhLCBDYW5hZGEuJiN4RDtCQyBDYW5jZXIgQWdlbmN5LCBWYW5jb3V2ZXIgQ2VudHJl
LCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYTsgRGVwYXJ0bWVudCBvZiBTdXJn
ZXJ5LCBVbml2ZXJzaXR5IG9mIEJyaXRpc2ggQ29sdW1iaWEsIFZhbmNvdXZlciwgQnJpdGlzaCBD
b2x1bWJpYSwgQ2FuYWRhLiBFbGVjdHJvbmljIGFkZHJlc3M6IGdkdW5jYW5AYmNjYW5jZXIuYmMu
Y2EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QVNDRU5ERS1SVDogQW4gQW5hbHlzaXMg
b2YgSGVhbHRoLVJlbGF0ZWQgUXVhbGl0eSBvZiBMaWZlIGZvciBhIFJhbmRvbWl6ZWQgVHJpYWwg
Q29tcGFyaW5nIExvdy1Eb3NlLVJhdGUgQnJhY2h5dGhlcmFweSBCb29zdCBXaXRoIERvc2UtRXNj
YWxhdGVkIEV4dGVybmFsIEJlYW0gQm9vc3QgZm9yIEhpZ2gtIGFuZCBJbnRlcm1lZGlhdGUtUmlz
ayBQcm9zdGF0ZSBDYW5jZXI8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SW50IEogUmFkaWF0IE9u
Y29sIEJpb2wgUGh5czwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+SW50ZXJuYXRpb25hbCBq
b3VybmFsIG9mIHJhZGlhdGlvbiBvbmNvbG9neSwgYmlvbG9neSwgcGh5c2ljczwvYWx0LXRpdGxl
PjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkludCBKIFJhZGlhdCBPbmNvbCBCaW9s
IFBoeXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5JbnRlcm5hdGlvbmFsIGpvdXJuYWwgb2YgcmFkaWF0
aW9uIG9uY29sb2d5LCBiaW9sb2d5LCBwaHlzaWNzPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQt
cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnQgSiBSYWRpYXQgT25jb2wgQmlvbCBQaHlzPC9mdWxs
LXRpdGxlPjxhYmJyLTE+SW50ZXJuYXRpb25hbCBqb3VybmFsIG9mIHJhZGlhdGlvbiBvbmNvbG9n
eSwgYmlvbG9neSwgcGh5c2ljczwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjU4MS01
ODk8L3BhZ2VzPjx2b2x1bWU+OTg8L3ZvbHVtZT48bnVtYmVyPjM8L251bWJlcj48ZWRpdGlvbj4y
MDE3LzA2LzA2PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BY3Rpdml0aWVzIG9mIERhaWx5
IExpdmluZzwva2V5d29yZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQsIDgw
IGFuZCBvdmVyPC9rZXl3b3JkPjxrZXl3b3JkPkFuZHJvZ2VuIEFudGFnb25pc3RzL3RoZXJhcGV1
dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5BbnRpbmVvcGxhc3RpYyBBZ2VudHMsIEhvcm1vbmFs
L3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5CcmFjaHl0aGVyYXB5LyptZXRob2Rz
PC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+
Rmx1dGFtaWRlL2FkbWluaXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5d29yZD48a2V5d29yZD5H
b25hZG90cm9waW4tUmVsZWFzaW5nIEhvcm1vbmUvYWdvbmlzdHM8L2tleXdvcmQ+PGtleXdvcmQ+
SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkludGVudGlvbiB0byBUcmVhdCBBbmFseXNpczwva2V5
d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3Jk
PjxrZXl3b3JkPlByb3N0YXRpYyBOZW9wbGFzbXMvZHJ1ZyB0aGVyYXB5LypyYWRpb3RoZXJhcHk8
L2tleXdvcmQ+PGtleXdvcmQ+KlF1YWxpdHkgb2YgTGlmZTwva2V5d29yZD48a2V5d29yZD5SZS1J
cnJhZGlhdGlvbi8qbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5SaXNrPC9rZXl3b3JkPjxrZXl3
b3JkPlNleHVhbCBCZWhhdmlvcjwva2V5d29yZD48a2V5d29yZD5TdXJ2ZXlzIGFuZCBRdWVzdGlv
bm5haXJlczwva2V5d29yZD48a2V5d29yZD5UaW1lIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+
VXJpbmF0aW9uIERpc29yZGVycy9ldGlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48
eWVhcj4yMDE3PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsIDE8L2RhdGU+PC9wdWItZGF0ZXM+
PC9kYXRlcz48aXNibj4wMzYwLTMwMTY8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjg1ODEzOTg8L2Fj
Y2Vzc2lvbi1udW0+PHVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDE2
L2ouaWpyb2JwLjIwMTcuMDIuMDI3PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRh
dGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5l
bmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlJvZGRhPC9BdXRob3I+
PFllYXI+MjAxNzwvWWVhcj48UmVjTnVtPjEyPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4x
MjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Ijlhdno1dHQw
Nng5MGQ0ZTB0emt2d3NlOHAyeHdhd3BkeHp2YSIgdGltZXN0YW1wPSIxNTQ0NTg5MjQzIj4xMjwv
a2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9y
ZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+Um9kZGEsIFMuPC9hdXRob3I+
PGF1dGhvcj5UeWxkZXNsZXksIFMuPC9hdXRob3I+PGF1dGhvcj5Nb3JyaXMsIFcuIEouPC9hdXRo
b3I+PGF1dGhvcj5LZXllcywgTS48L2F1dGhvcj48YXV0aG9yPkhhbHBlcmluLCBSLjwvYXV0aG9y
PjxhdXRob3I+UGFpLCBILjwvYXV0aG9yPjxhdXRob3I+TWNLZW56aWUsIE0uPC9hdXRob3I+PGF1
dGhvcj5EdW5jYW4sIEcuPC9hdXRob3I+PGF1dGhvcj5Nb3J0b24sIEcuPC9hdXRob3I+PGF1dGhv
cj5IYW1tLCBKLjwvYXV0aG9yPjxhdXRob3I+TXVycmF5LCBOLjwvYXV0aG9yPjwvYXV0aG9ycz48
L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkJyaXRpc2ggQ29sdW1iaWEgKEJDKSBDYW5jZXIg
QWdlbmN5LCBWYW5jb3V2ZXIgQ2VudHJlLCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENh
bmFkYS4mI3hEO0JyaXRpc2ggQ29sdW1iaWEgKEJDKSBDYW5jZXIgQWdlbmN5LCBWYW5jb3V2ZXIg
Q2VudHJlLCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYTsgRGVwYXJ0bWVudCBv
ZiBTdXJnZXJ5LCBVbml2ZXJzaXR5IG9mIEJyaXRpc2ggQ29sdW1iaWEsIFZhbmNvdXZlciwgQnJp
dGlzaCBDb2x1bWJpYSwgQ2FuYWRhLiYjeEQ7QnJpdGlzaCBDb2x1bWJpYSAoQkMpIENhbmNlciBB
Z2VuY3ksIFZhbmNvdXZlciBDZW50cmUsIFZhbmNvdXZlciwgQnJpdGlzaCBDb2x1bWJpYSwgQ2Fu
YWRhOyBEZXBhcnRtZW50IG9mIFN1cmdlcnksIFVuaXZlcnNpdHkgb2YgQnJpdGlzaCBDb2x1bWJp
YSwgVmFuY291dmVyLCBCcml0aXNoIENvbHVtYmlhLCBDYW5hZGEuIEVsZWN0cm9uaWMgYWRkcmVz
czogam1vcnJpc0BiY2NhbmNlci5iYy5jYS4mI3hEO0RlcGFydG1lbnQgb2YgU3VyZ2VyeSwgVW5p
dmVyc2l0eSBvZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEs
IENhbmFkYTsgQkMgQ2FuY2VyIEFnZW5jeSwgQ2VudHJlIGZvciB0aGUgU291dGhlcm4gSW50ZXJp
b3IsIEtlbG93bmEsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYS4mI3hEO0RlcGFydG1lbnQgb2Yg
U3VyZ2VyeSwgVW5pdmVyc2l0eSBvZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRp
c2ggQ29sdW1iaWEsIENhbmFkYTsgQkMgQ2FuY2VyIEFnZW5jeSwgVmFuY291dmVyIElzbGFuZCBD
ZW50cmUsIFZpY3RvcmlhLCBCcml0aXNoIENvbHVtYmlhLCBDYW5hZGEuJiN4RDtTdW5ueWJyb29r
IEhlYWx0aCBTY2llbmNlcyBDZW50cmUsIFRvcm9udG8sIE9udGFyaW8sIENhbmFkYTsgRGVwYXJ0
bWVudCBvZiBSYWRpYXRpb24gT25jb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVG9yb250bywgVG9yb250
bywgT250YXJpbywgQ2FuYWRhLiYjeEQ7RGVwYXJ0bWVudCBvZiBQb3B1bGF0aW9uIE9uY29sb2d5
LCBCQyBDYW5jZXIgQWdlbmN5LCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYS4m
I3hEO0JyaXRpc2ggQ29sdW1iaWEgKEJDKSBDYW5jZXIgQWdlbmN5LCBWYW5jb3V2ZXIgQ2VudHJl
LCBWYW5jb3V2ZXIsIEJyaXRpc2ggQ29sdW1iaWEsIENhbmFkYTsgRGVwYXJ0bWVudCBvZiBNZWRp
Y2luZSwgVW5pdmVyc2l0eSBvZiBCcml0aXNoIENvbHVtYmlhLCBWYW5jb3V2ZXIsIEJyaXRpc2gg
Q29sdW1iaWEsIENhbmFkYS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5BU0NFTkRFLVJU
OiBBbiBBbmFseXNpcyBvZiBUcmVhdG1lbnQtUmVsYXRlZCBNb3JiaWRpdHkgZm9yIGEgUmFuZG9t
aXplZCBUcmlhbCBDb21wYXJpbmcgYSBMb3ctRG9zZS1SYXRlIEJyYWNoeXRoZXJhcHkgQm9vc3Qg
d2l0aCBhIERvc2UtRXNjYWxhdGVkIEV4dGVybmFsIEJlYW0gQm9vc3QgZm9yIEhpZ2gtIGFuZCBJ
bnRlcm1lZGlhdGUtUmlzayBQcm9zdGF0ZSBDYW5jZXI8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+
SW50IEogUmFkaWF0IE9uY29sIEJpb2wgUGh5czwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+
SW50ZXJuYXRpb25hbCBqb3VybmFsIG9mIHJhZGlhdGlvbiBvbmNvbG9neSwgYmlvbG9neSwgcGh5
c2ljczwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkludCBKIFJh
ZGlhdCBPbmNvbCBCaW9sIFBoeXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5JbnRlcm5hdGlvbmFsIGpv
dXJuYWwgb2YgcmFkaWF0aW9uIG9uY29sb2d5LCBiaW9sb2d5LCBwaHlzaWNzPC9hYmJyLTE+PC9w
ZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnQgSiBSYWRpYXQgT25jb2wg
QmlvbCBQaHlzPC9mdWxsLXRpdGxlPjxhYmJyLTE+SW50ZXJuYXRpb25hbCBqb3VybmFsIG9mIHJh
ZGlhdGlvbiBvbmNvbG9neSwgYmlvbG9neSwgcGh5c2ljczwvYWJici0xPjwvYWx0LXBlcmlvZGlj
YWw+PHBhZ2VzPjI4Ni0yOTU8L3BhZ2VzPjx2b2x1bWU+OTg8L3ZvbHVtZT48bnVtYmVyPjI8L251
bWJlcj48ZWRpdGlvbj4yMDE3LzA0LzI0PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZ2Vk
PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQsIDgwIGFuZCBvdmVyPC9rZXl3b3JkPjxrZXl3b3JkPkFu
ZHJvZ2VuIEFudGFnb25pc3RzL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRpYyB1c2U8L2tleXdv
cmQ+PGtleXdvcmQ+QnJhY2h5dGhlcmFweS8qYWR2ZXJzZSBlZmZlY3RzL21ldGhvZHM8L2tleXdv
cmQ+PGtleXdvcmQ+Q29tYmluZWQgTW9kYWxpdHkgVGhlcmFweS9hZHZlcnNlIGVmZmVjdHMvbWV0
aG9kczwva2V5d29yZD48a2V5d29yZD5EaWFycmhlYS9lcGlkZW1pb2xvZ3kvZXRpb2xvZ3k8L2tl
eXdvcmQ+PGtleXdvcmQ+RGlzZWFzZS1GcmVlIFN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPkVy
ZWN0aWxlIER5c2Z1bmN0aW9uL2VwaWRlbWlvbG9neS8qZXRpb2xvZ3k8L2tleXdvcmQ+PGtleXdv
cmQ+RmVhc2liaWxpdHkgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5GZWNhbCBJbmNvbnRpbmVu
Y2UvZXBpZGVtaW9sb2d5LypldGlvbG9neTwva2V5d29yZD48a2V5d29yZD5Gb2xsb3ctVXAgU3R1
ZGllczwva2V5d29yZD48a2V5d29yZD5HYXN0cm9pbnRlc3RpbmFsIEhlbW9ycmhhZ2UvZXBpZGVt
aW9sb2d5L2V0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkdvbmFkb3Ryb3Bpbi1SZWxlYXNpbmcg
SG9ybW9uZS9hZHZlcnNlIGVmZmVjdHMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3Jk
Pkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+SW50
ZW50aW9uIHRvIFRyZWF0IEFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkxvZ2lzdGljIE1vZGVs
czwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9r
ZXl3b3JkPjxrZXl3b3JkPlBlbHZpczwva2V5d29yZD48a2V5d29yZD5Qcm9zdGF0aWMgTmVvcGxh
c21zLypkcnVnIHRoZXJhcHkvKnJhZGlvdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5SYWRpb3Ro
ZXJhcHkgRG9zYWdlPC9rZXl3b3JkPjxrZXl3b3JkPlJhZGlvdGhlcmFweSwgQ29uZm9ybWFsLyph
ZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+UmUtSXJyYWRpYXRpb24vYWR2ZXJzZSBl
ZmZlY3RzL21ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+UmVjdHVtL3JhZGlhdGlvbiBlZmZlY3Rz
PC9rZXl3b3JkPjxrZXl3b3JkPlRpbWUgRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5VcmluYXJ5
IEluY29udGluZW5jZS9lcGlkZW1pb2xvZ3kvZXRpb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VXJp
bmF0aW9uIERpc29yZGVycy9lcGlkZW1pb2xvZ3kvKmV0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk
PlVyb2dlbml0YWwgU3lzdGVtL3JhZGlhdGlvbiBlZmZlY3RzPC9rZXl3b3JkPjwva2V5d29yZHM+
PGRhdGVzPjx5ZWFyPjIwMTc8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KdW4gMTwvZGF0ZT48L3B1
Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAzNjAtMzAxNjwvaXNibj48YWNjZXNzaW9uLW51bT4yODQz
MzQzMjwvYWNjZXNzaW9uLW51bT48dXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVt
PjEwLjEwMTYvai5panJvYnAuMjAxNy4wMS4wMDg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxy
ZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxh
bmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=
ADDIN EN.CITE.DATA (Morris, Tyldesley et al. 2017, Rodda, Morris et al. 2017, Rodda, Tyldesley et al. 2017) was assessed to be at low risk of bias for survival outcomes (Table 3). The retrospective cohort study PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2huc29uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2huc29uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48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ADDIN EN.CITE.DATA (Johnson, Lester-Coll et al. 2017) was assessed to be at high risk of bias overall. Further, the CA also highlighted the applicability issues associated with the pivotal RCT (ASDENDE-RT) which included around half of the population with low-intermediate risk prostate cancer. The Critique also highlighted that the CA adopted a modified version of the NCCN Prostate Cancer Risk Group, Intermediate-Risk, to represent the high-intermediate risk group considered in the application (without a clear statement explaining why this modified version was used). However, the Critique deduced that the requirement for Gleason 7 and T2bc (in the CA definition) rather than the option for Gleason 7 and T2bc (in the NCCN definition), indicates that patients with these clinical characteristics represent patients who are of higher risk in the intermediate group, thereby moving them into the high-intermediate risk group.Table 3Balance of clinical benefits and harms of EBRT plus LDR-BT boost, relative to DE-EBRT, and as measured by the critical patient-relevant outcomes in the key studies Outcomes (units)Follow-upParticipants (studies)Quality of evidence (GRADE) aHazard ratio (95%CI; p-valueCommentsb-PFS Median follow-up 6.5 years1 RCTN=398???? MODERATEHR = 0.49 (0.30-0.80; p=0.004)RCTs start at high quality in GRADE. Downgraded for serious indirectness as around half the population comprises low intermediate risk patients (which does not align with the intended target population).OS (for RCT)Median follow-up 6.5 years1 RCTN=398???? LOWHR = 0.88 (0.54-1.45; p=0.62)Downgraded for serious imprecision due to wide confidence intervals and as the trial was small and was not powered to measure the outcome.Downgraded for indirectness as around half the population comprises low intermediate risk patients.OS (for observational study)Median follow-up of 63 months1 CohortN=25,436????VERY LOWHR=0.74, (0.66–0.89)Observational studies start at low quality in grade.Downgraded for very serious risk of bias. Downgraded for serious indirectness due to lack of detailed reporting of interventions delivered.MFS Median follow-up 6.5 years1 RCTN=398???? LOWHR = 0.99 (0.51–1.96; p=0.99)Downgraded for serious imprecision due to wide confidence intervals and as the trial was small and was not powered to measure the outcome.Downgraded for serious indirectness as around half the population comprises low intermediate risk patients.PCSS Median follow-up 6.5 years1 RCTN=398???? LOWHR = 0.71 (0.27 – 1.88; p=0.49)Downgraded for serious imprecision due to wide confidence intervals and as the trial was small and was not powered to measure the outcome.Downgraded for serious indirectness as around half the population comprises low intermediate risk patients.Adverse effectsMedian follow-up 6.5 years1 RCTN=383???? LOWLDR-BT boost arm had a higher number of adverse effects (GI and GU morbidity and erectile dysfunction) compared to DE-EBRT boost arm.Downgraded for unclear risk of reporting bias (because adverse data were not reported in the format as specified). Downgraded for serious imprecision as the trial was small and was not powered to measure the outcome. Although around half the population comprises low intermediate risk patients, treatment-related adverse events would be experienced across all risk groups and therefore indirectness was not considered to be a serious concern (therefore evidence was not downgraded for this outcome)HRQoLMedian follow-up was 6 years1 RCTN=357???? LOWSignificantly larger drop in mean HRQoL scores (compared with baseline) in the LDR-BT boost arm compared to DE-EBRT boost arm for some SF36v2 measures.Downgraded for unclear risk of detection bias (because a lack of blinding is likely to influence patient-reported outcomes). Downgraded for serious imprecision as the trial was small and was not powered to measure the outcome.Although the population was indirect, as around half the population comprises low intermediate risk patients, this outcome was not downgraded for indirectness, as it is unlikely to seriously affect this outcome.a GRADE Working Group grades of evidence (Guyatt et al., 2013) ???? High quality: We are very confident that the true effect lies close to that of the estimate of effect. ???? Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. ???? Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.???? Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.Abbreviations: b-PFS=biochemical progression-free survival; EBRT=external beam radiation therapy; GS=Gleason sum; HRQoL=health-related quality of life; LDR-BT=low-dose rate brachytherapy; MFS=metastasis-free survival; OS=overall survival; PCSS=prostate cancer-specific survival; RCT=randomised controlled trial; GI=gastrointestinal; GU=genitourinary; SF36v2= Short Form 36 version 2; Bold = statistically significantVs. EBRT+HDT-BT boostNo data were identified comparing the effectiveness of EBRT+LDR-BT boost to EBRT+HDR-BT boost in people with high-intermediate and high-risk prostate cancer.Clinical ClaimIt is suggested that, relative to DE-EBRT, EBRT plus LDR-BT boost has inferior safety and superior effectiveness for biochemical progression-free survival (b-PFS), and uncertain effectiveness for overall survival (OS), metastasis-free survival (MFS) and prostate cancer-specific survival (PCSS) in men with high-intermediate and high-risk prostate cancer.Given the paucity of evidence for the population of men with high-intermediate or high-risk prostate cancer, it is suggested that, relative to EBRT plus HDR-BT boost and RP, EBRT plus LDR-BT boost has uncertain safety. Post-ESC AddendumFor clarification on the population included in the ASCENDE-RT trial, a table (Table 4) of the relevant baseline characteristics (iPSA, Gleason sum and clinical T stages) applicable to the population definitions of this application (high-intermediate and high risk) was provided.Table 4 Baseline characteristics in ASCENDE-RT?Baseline characteristic?Baseline proportion?iPSA (ng/mL)??10 - 20?33.2%?>20?18.2%?Gleason sum???7?53.8%?8-10?40.7%?Clinical T stage???T1c-T2c?70.9%?T3a?29.1%?Table 4 shows that for high-intermediate risk, defined as PSA>10.0-<20.0 ng/mL and Gleason score 7 and stage T2b-c, it cannot be determined exactly the proportion of patients that would have all three of these criteria. PSA>10.0-<20.0 ng/mL is 33.2%, Gleason sum of 7 is 53.8% and clinical T stages T2b-c is not reported separately and only reported as 70.9%. Therefore if all three criteria are to be fulfilled, then the proportion of patients can be assumed to be ≤33.2%.High risk is defined as PSA>20.0 ng/mL and/or Gleason score 8-10 and/or stage T3a. PSA>20.0 ng/mL is 18.2%, Gleason sum of 8-10 is 40.7% and clinical T stage T3a is 29.1%. As this is and/or criteria, the proportion of patients can be assumed to be ≥40.7%.In total, it can be assumed that approximately 73.9% of the ASCENDE trial is applicable to the population of the current application, however the exact percentage is uncertain.Economic evaluationPre-ESC modelA cost-utility analysis was presented comparing EBRT+LDR-BT boost with DE-EBRT (Table 5).Table 5Summary of the economic evaluation PerspectiveAustralian healthcare systemComparatorDose-escalated external beam radiation therapy (DE-EBRT)Type of economic evaluationCost-utility analysisSources of evidenceRCT, observational studiesTime horizon10 yearsOutcomesLYG and QALYs gainedMethods used to generate resultsDecision analytic Markov modelHealth statesEight health sates: Remission, acute toxicity GI/GU all grades (first 6 months), late toxicity (GI/GU) grade ≥3, biochemical failure without late toxicity, biochemical failure with late toxicity, metastases, prostate cancer death, all-cause death (other causes)Cycle length12 monthsDiscount rate5%Software packages usedTreeAge Pro 2018, 18.2.1-v20180828The model structure was based on a published Markov model by Carter, Martin et al. (2014), which was considered appropriate by the Critique. Key structural assumptions of the CAs model included grouping acute GI and GU toxicities together as a single health state; excluding the probability of transiting to metastatic disease without biochemical failure and that prostate cancer death would be preceded by the metastases health state regardless of the proximate cause of death. The Critique stated that these assumptions were reasonable. However, the Pre-ESC response highlighted potential structural modelling errors (e.g. no option to progress from late toxicity to remission without toxicity or to biochemical failure without toxicity) and errors estimating model transitional probabilities (e.g. substantially higher transitional probability of biochemical failure to metastases was applied to intervention arm compared with comparator arm (0.043 vs. 0.108, respectively), which it claimed made no clinical sense. The Pre-ESC Response noted both potential errors favoured the comparator.The overall costs and outcomes, and incremental costs and outcomes (QALYs and life years [LYs]) as calculated for the intervention and comparator in the model, and using the base case assumptions, are shown in Table 6 and Table 7, respectively. The CA explained that incremental LYs was higher as overall survival (both prostate cancer- and noncancer-related) was higher for the LDR-BT boost (relative to DE-EBRT). However, incremental QALYs was lower due to higher toxicity experienced by patients undergoing LDR-BT (relative to DE-EBRT).Table 6 Base case incremental cost effectiveness ratio – high-intermediate and high risk: QALY outcomesCostIncremental costEffectiveness (QALYs)Incremental effectivenessICERLDR-BT boost$27,866.37$8,072.407.01-0.04Dominated (more expensive, less effective)DE-EBRT$19,793.97-7.05--Abbreviations: DE-EBRT=dose-escalated external beam radiation therapy; ICER=Incremental Cost Effectiveness Ratio; LDR-BT=low-dose rate brachytherapy; QALYs=quality-adjusted life yearsTable 7 Base case Incremental costs and effectiveness – high-intermediate risk and high risk: LY outcomesCostIncremental costEffectiveness (LYs)Incremental effectivenessICERLDR-BT boost$27,866.37$8,072.407.480.03$237,027.21DE-EBRT$19,793.97-7.45--Abbreviations: DE-EBRT=dose-escalated external beam radiation therapy; ICER=Incremental Cost Effectiveness Ratio; LDR-BT=low-dose rate brachytherapy; LYs = Life yearsThe CA stated that the economic model conclusions were robust across a range of plausible estimates (Figure 3). In addition, LDR-BT boost was also unlikely to be cost-effective compared with DE-EBRT over a 20 or 30 year time horizon. The Critique stated there were several minor errors within the economic evaluation, but these did not impact on the results.Figure 3Tornado diagram. One-way sensitivity analysis LDR-BT boost versus DE-EBRTThe CA validated the ICER by comparing the modelled 10-year survival curve estimates with overall survival estimates from the ASCENDE-RT trial and study by Johnson, Lester Coll et al. 2017. The CA stated that the model provided a similar overall survival curve for the LDR-BT boost arm; however, it was overestimated for the DE-EBRT arm (0.87 vs. 0.7 and 0.78, respectively). Post-ESC model: Addendum The CA addressed several modelling issues raised during ESC (and raised by the applicant):The model structure was amended to allow patients to enter biochemical failure with without late toxicity following GU/GI late toxicity grade3+;The transitional probability from biochemical failure to metastases was adjusted to align with clinical data inputs (ASCENDE-RT); andThe transitional probability from remission without toxicity to biochemical failure without late toxicity was corrected for a coding error.In addition, the CA group confirmed with a local expert that the derivation of utility weights in the pre-ESC model was correct and thus no changes were made to the Post-ESC model.The results of the revised model is summarised for QALY outcomes (Table 8) and LYs (Table 9).Table 8Base case incremental costs and effectiveness – high-intermediate risk and high-risk prostate cancer: QALY outcomesCostIncremental costEffectiveness (QALYs)Incremental effectivenessICERLDR-BT boost (over 10 years)$21,840.00$2,886.007.050.17$16,976/QALYDE-EBRT (over 10 years)$18,954.00-6.88-Abbreviations: DE-EBRT=Dose-escalated external beam radiotherapy; ICER=Incremental Cost Effectiveness Ratio; LDR-Brachytherapy=Low-dose rate Brachytherapy; QALY=quality-adjusted life-yearsTable 9Base case incremental costs and effectiveness – high-intermediate risk and high-risk prostate cancer: LY outcomesCostIncremental costEffectiveness (LYs)Incremental effectivenessICERLDR-BT boost (over 10 years)$21,840.00$2,886.007.490.04$80,5444/LYDE-EBRT (over 10 years)$18,954.00-7.46-Abbreviations: DE-EBRT=Dose-escalated external beam radiotherapy; ICER=Incremental Cost Effectiveness Ratio; LDR-Brachytherapy=Lowdose rate Brachytherapy; LY=Life-yearsThe CA stated that the economic model was most sensitive to the utility gained in the health state for biochemical failure with late toxicity (Figure 4).Figure 4Tornado diagram. One-way sensitivity analysis LDR-BT boost versus DE-EBRTFinancial/budgetary impactsPre-ESC financialsAn epidemiological approach has been used to estimate the financial implications to the MBS of introducing LDR-BT boost for patients with high-intermediate and high-risk prostate cancer (Table 10).The proposed item costs of LDR-BT boost are $935.60 for the radiation oncology component and $1,044.20 for the urological component of radioactive seed implantation. The direct cost of LDR-BT boost items (five items including seed implantation, brachytherapy planning, transrectal ultrasound and radiation source localisation) is $2,521.70, considering 75% rebate for urological component of seed implantation and transrectal ultrasound and 85% rebate for radiation oncology items. Table 10 Total costs to the MBS associated with LDR-BT boostDescription20202021202220232024LDR-BT boost-----Number of services106.70110.69115.57119.60123.62Sub-total cost* $269,059.35 $279,127.37 $291,431.27 $301,582.96 $311,734.65 Increased usage services currently MBS listed (co-administered and adverse-effect treatment-related)-----Number of services 106.70110.69115.57119.60123.62Sub-total cost*Critique’s values $96,439.00 $96,670.67 $100,047.68$100,288.02 $104,457.77 $104,708.70 $108,096.44$108,356.12 $111,735.12 $112,003.53Decreased usage services currently MBS listed (HDR-BT boost)-----Number of services 106.70110.69115.57119.60123.62Sub-total cost* -$313,951.47 -$325,699.34 -$340,056.12 -$351,901.60 -$363,747.09 Total costCritique’s values $51,546.87$51,778.54 $53,475.72$53,716,06 $55,832.92 $56,038.86 $57,777.80$58,037.48 $59,722.68$59,991.10 * Medical services delivered in inpatient settings were calculated at 75% of MBS fee. If it was deemed feasible to deliver a service in outpatient settings, 85% of total fee was used.Abbreviations: HDR-BT=high-dose rate brachytherapy; LDR-BT=low-dose rate brachytherapyThe Critique stated consideration should have been given to the impact on PBS of funding LDR-BT boost, at a minimum, the cost of hormone therapy (leuprorelin) when used to treat patients who progress to biochemical failure. For MBS impacts (with the exception of higher uptake for LDR-BT boost), there is potential for the net cost per year to be less than estimated in the CA.Post- ESC financials: Addendum An additional analysis was conducted to account for the overall financial impact of LDR-BT boost compared with DE-EBRT, using the inputs from the cost-effectiveness model (Markov traces). Specifically, costs in the CEA model were grouped into four categories: MBS costs, PBS costs, hospital costs, and prosthesis costs. The CA presented the results as per the base case model presented to ESC (Table 11) and revised model presented post ESC, in the Addendum (Table 12).Table 11 Revised Pre-ESC model: Total forecasted services, overall deconstructed costs for each treatment arm and the difference between the treatment arms between 2020 and 2024 using outputs from the base case model.Description20202021202220232024Total services107111116120124LDR-BT boostPBS Costs$10,447$17,060$33,570$62,267$104,753MBS$177,882$208,730$246,676$289,140$337,354Hospital$272,719$309,632$377,084$471,599$595,465Prosthesis$329,436$341,755$356,822$369,265$381,677TOTAL COST$790,485$877,178$1,014,153$1,192,271$1,419,250DE-EBRTPBS Costs$6,961$13,434$27,046$47,764$75,567MBS$433,579$475,952$526,388$577,784$633,126Hospital$0$23,828$72,941$146,384$243,019Prosthesis$0$0$0$0$0TOTAL COST$440,540$513,214$626,375$771,932$951,712DifferencePBS Costs$3,486$3,626$6,524$14,502$29,187MBS-$255,696-$267,222-$279,712-$288,643-$295,772Hospital$272,719$285,804$304,143$325,215$352,446Prosthesis$329,436$341,755$356,822$369,265$381,677TOTAL COST$349,945$363,964$387,777$420,339$467,537Table 12 Revised Post-ESC model: Total forecasted services, overall deconstructed costs for each treatment arm and the difference between the treatment arms between 2020 and 2024 using outputs from the amended model.Description20202021202220232024Total services107111116120124LDR-BT boostPBS Costs$790,485$877,178$1,006,112$1,162,435$1,349,915MBS$10,447$17,060$29,706$47,985$71,701Hospital$177,882$208,730$246,014$286,687$331,667Prosthesis$272,719$309,632$373,570$458,497$564,871TOTAL COST$329,436$341,755$356,822$369,265$381,677DE-EBRTPBS Costs$440,540$513,214$625,228$768,154$943,556MBS$6,961$13,434$26,304$45,511$71,019Hospital$433,579$475,952$528,637$584,232$645,478Prosthesis$0$23,828$70,287$138,410$227,059TOTAL COST$0$0$0$0$0DifferencePBS Costs$349,945$363,964$380,884$394,281$406,360MBS$3,486$3,626$3,402$2,474$682Hospital-$255,696-$267,222-$282,623-$297,545-$313,812Prosthesis$272,719$285,804$303,283$320,087$337,812TOTAL COST$329,436$341,755$356,822$369,265$381,677Key issues from ESC for MSACKey Issues from ESC to MSACESC advice to MSACIs the data from the RCT of high enough quality? Does effectiveness (biochemical progression-free survival) balance adverse effects and their QoL effect?The ASCENDE-RT trial showed superior effectiveness of EBRT + LDR-BT compared with dose escalated (DE)–EBRT, but with inferior safety and lower health-related QoL scores. The Critique downgraded the evidence from the trial, but this may not be appropriate.Are the adverse events reported in the trial still representative?Adverse events observed in the trial may be avoidable with improvements in planning and imaging techniques since the trial was conducted.Item descriptor needs to be refined Avoid use of ‘recommended’ in statement specifying that LDR-BT is to be used only as a ‘boost’ treatment after EBRT. Retain ‘in association with [a radiation oncologist/urologist]’ to ensure the radiology oncology and urology components of the procedure are done together. Stipulate that LDR-BT would also be in addition to androgen blockade.Issues with model:transition between remission and late GU/GI toxicity should be two-wayincorrect transition probability from biochemical failure to metastasesutility decrement for acute and late adverse events derived using EQ-5D?3L rather than EQ-5D?5Lquery whether utility decrement for acute grade toxicity has been carried throughModel should be checked and verified, and the analysis re-run. Corrections will affect the ICER significantly and likely favour the intervention.Corrected model should use Australian utility weightsMapping from SF-36 using Australian SF-6D algorithms will require data for individual item levels. Check whether applicant has access to study item data. Net cost per year may be lower than that estimated in the Contracted AssessmentFurther cost offsets should be considered: cost of treating adverse events after HDR-BT PBS cost of hormone therapy to treat patients who progress to biochemical failure.ESC discussionApplication 1525 requests Medicare Benefits Schedule (MBS) listing of low dose-rate brachytherapy (LDR-BT) as a boost following external beam radiation therapy (EBRT) in the treatment of high-intermediate and high-risk prostate cancer. ESC recalled that LDR-BT is already included on the MBS for low-risk prostate cancer.For the purposes of this application, high-intermediate risk is defined as PSA>10.0–<20.0?ng/mL and Gleason score?7 and stage T2b–c, while high risk is defined as PSA>20.0?ng/mL and/or Gleason score 8–10 and/or stage T3a. ESC noted the importance of the differentiation between ‘and’ and ‘and/or’ in these definitions. A patient does not need to meet all three criteria in the high risk definition to be considered high risk.ESC noted the Critique’s comment that the populations included in the primary sources of evidence – the ASCENDE-RT randomised controlled trial (RCT) and a retrospective cohort study (Johnson et?al., 2017) – were more extensive than those proposed in the PICO. Definitions of intermediate and high risk in these studies were based on National Comprehensive Cancer Network (NCCN) risk strata. ESC noted that the designation of intermediate and high risk is arbitrary from a clinical point of view and queried which definition of intermediate risk should be used (NCCN or PICO).ESC considered that the proposed fees for the radiology oncology and urology components of the procedure are appropriate and in line with existing brachytherapy items.ESC noted that the item descriptor needs to be reworded to avoid the use of ‘recommended’ with regard to LDR-BT being used only as a ‘boost’ treatment after EBRT. ESC noted the Department’s proposed wording: ‘For the populations this procedure will be rebated if it is performed as a “boost” treatment, in addition to external beam radiotherapy, at an approved site.’ And that [a radiation oncologist/urologist]’ should be retained in the descriptor to ensure the radiology oncology and urology components of the procedure are done together.ESC also noted that the item descriptor should be further refined to stipulate that LDR-BT would also be in addition to androgen blockade, which is standard practice in Australia and consistent with the ASCENDE-RT trial.ESC noted that the one of the comparators in practice would be surgery. However, the item descriptor does not indicate when to use LDR-BT instead of surgery. There is no direct evidence comparing LDR-BT boost with surgery; the comparator in the trial was dose escalated (DE)–EBRT.ESC noted that, although the ASCENDE-RT trial was well designed and had a low risk of bias, the Critique applied a low certainty rating to the data because ‘around half the population comprises low intermediate risk patients’. However, the applicant disputed this, claiming that the Critique based this judgement on a misinterpretation of the definition of high risk. The applicant reiterated that the baseline characteristics of the ASCENDE-RT trial population were based on NCCN risk strata and the majority of patients in the trial were at high risk. ESC noted that the conclusions in the Critique and Contracted Assessment about the quality of the trial are difficult to reconcile, and downgrading may not have been appropriate.ESC noted that the ASCENDE-RT trial showed late genitourinary (GU) and gastrointestinal (GI) adverse effects were more frequent in the EBRT + LDR-BT boost arm than in the DE-EBRT arm, and health-related quality of life (QoL) scores were lower. However, there was no significant difference in serious adverse events. ESC noted that, importantly, there were no differences in the frequency of erectile dysfunction. ESC commented that although GU and GI side-effects affect patients’ QoL, they pass and are treatable; consumer feedback indicates that irreversible erectile dysfunction is of more importance to patients. ESC considered that adverse events observed in the trial may be avoidable with improvements in planning and modern imaging techniques that have occurred since the trial was conducted.ESC noted that adverse events in the ASCENDE-RT trial were balanced by superior effectiveness for biochemical progression-free survival (b-PFS), the primary outcome, for those receiving LDR-BT boost compared with DE-EBRT; however, there was no difference in overall survival, metastasis-free survival or prostate cancer–specific survival.ESC noted that the differences between the two arms of the ASCENDE-RT trial were well accounted for, but the study was not powered or long enough to assess survival outcomes.ESC noted that the retrospective cohort study showed better overall survival for EBRT + LDR-BT boost than for DE-EBRT. However, ESC agreed with the Critique that this study is at a high risk of bias and low applicability because the majority of patients were at low-intermediate risk. ESC noted that survival data from this study were not used in the economic model.ESC noted that cost utility analysis was appropriate, and the 10-year time horizon is consistent with the RCT and appropriate for the target population.ESC noted a structural issue with the model (raised by the applicant) in that it does not allow for remission of patients with late GU/GI toxicity. ESC noted that some of these late events may resolve with treatment, and there is evidence from the RCT that some of these events are transitory. The applicant claimed that the model should have included options to progress from late toxicity to remission without toxicity or to biochemical failure without toxicity. Not allowing for this in the model would overestimate the QoL detriment of adverse events, as patients enter the late toxicity state and remain there, accruing costs but with lower utility. ESC agreed with the submission that this would have a significant effect on the incremental cost-effectiveness ratio (ICER). ESC suggested a sensitivity analysis should be done on the proportions of patients with transitory events.ESC noted that the transition probabilities from acute toxicity to late toxicity make clinical sense. However, the transition probability from biochemical failure to metastases seems to be incorrect. The model gives a transition probability for LDR-BT boost that is 2.5-times higher than for DE-EBRT. This is a key driver in the model (with high cost and low utility) so will have a significant effect on the ICER. ESC agreed with the applicant that there is no reason for probability in the two arms to be different; there is no evidence from the trial that this is the case. ESC queried whether this may be a coding error in the model.ESC noted that a conditional probability (using the number of patients who progressed as a denominator) would be more appropriate than a transition probability. A corrected calculation resulted in a conditional probability of 0.085 (17/25×25/198 or 17/198) for LDR-BT boost versus 0.09 (18/51×51/200 or 18/200) for DE-EBRT. ESC recommended that probabilities be verified and corrected.ESC noted that changing the model structure and transitional probabilities will reduce costs, as acute GU/GI toxicity (all grades), late GU/GI toxicity (grade ≥3) and metastases make up the highest proportions of total incremental costs.ESC noted that changes in the model will also change QoL outcomes. ESC queried why there is no QoL included for acute GU/GI toxicity (all grades). ESC noted that the Contracted Assessment assumes that the utility decrement for acute grade toxicity symptoms starts at 12?months, but the model has no-one left in that health state beyond 12?months. ESC recommended that the model is checked to ensure that utilities are carried through in that state.ESC noted an issue with utility weights used in the model. SF-36 scores from the ASCENDE-RT trial were mapped to the EQ-5D index using the method by Ara and Brazier (2008), which ESC considered to be appropriate if only mean values were available from the trial. However, the EQ-5D?3L instrument that was used in this method has been largely replaced by the EQ-5D?5L. The utility decrement when a patient moves from one level to another (i.e.?no problems to some problems) is likely to be lower with the 5L instrument, which would favour the intervention. ESC agreed with the applicant that Australian utility weights should be used in the model. It is possible to map from SF-36 using SF-6D algorithms available for Australia. However, this would require data for individual item levels. ESC recommended checking whether the applicant has access to study item data to allow mapping to actual Australian utilities rather than EQ-5D.ESC noted the applicant’s claim that the utility weight used in the model for the remission without toxicity health state is too high and is inconsistent with other derived Australian utility scores. QoL values suggested by the applicant based on Australian algorithms were lower and would favour the intervention. ESC considered that using an Australian derived utility measure for remission may not be possible without changing the relative utility values. Other utility weights were derived from another paper, which ESC considered appropriate.ESC recommended that, to be able to draw any conclusions, the model should be verified and corrected before going to MSAC, to ensure it is consistent with the clinical pathway with regard to remission following late toxicity. Analysis should be re-run using:corrected metastasis transition probabilitieslower decrement for acute and late adverse events (using EQ-5D?5L instrument)Australian utility weights.ESC noted that these corrections will all likely favour the intervention, and will affect the ICER significantly.ESC considered that the epidemiological approach used to estimate financial implications is appropriate. ESC noted the potential for the net cost per year to be lower than that estimated in the Contracted Assessment. Cost offsets would be greater if the cost of treating adverse events after high dose-rate (HDR)-BT was included. The impact on the PBS should also have been considered (at least the cost of hormone therapy to treat patients who progress to biochemical failure).Other significant factorsNil.Applicant’s comments on MSAC’s Public Summary DocumentThe applicant had no comment.Further information on MSACMSAC Terms of Reference and other information are available on the MSAC Website: visit the MSAC website ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- science manuscript template theranostics
- sipuleucel t drug monograph pharmacy benefit management
- guide to anticoagulant therapy heparin
- intravenous immune globulin ivig is fda approved for a
- management of chronic non cancer pain
- purpose of application
- from the phoenix5 prostate cancer glossary
- alternative clinics metabolic therapy
Related searches
- purpose of rule of law
- purpose of report of contact
- purpose of school vs purpose of education
- purpose of nasw code of ethics
- purpose of board of nursing
- the purpose of the oath of enlistment
- purpose of certificate of incorporation
- purpose of or purpose for
- happiness is the meaning and the purpose of life the whole aim and end of human
- the purpose of each article of constitution
- the purpose of the blood of jesus
- the purpose of a chamber of commerce